Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Parasitol Res ; 116(2): 539-547, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27822584

RESUMEN

Antimalarial drug resistance is the main therapeutic challenge to the control of the disease, making the search for new compounds as alternative treatments of central importance. Propolis has a long history of medicinal use due to its antifungal, antibacterial and antiprotozoal properties. The present study therefore aimed to evaluate the antimalarial activity of the Saudi propolis methanolic extract against Plasmodium chabaudi infection in mice. To this end, albino mice were divided into five groups: the first group was the normal control; the second, third, fourth and fifth groups were infected intraperitoneally with 106 P. chabaudi-parasitized erythrocytes. The last three groups of mice were gavaged with 100 µl of propolis extract (PE) at a dose of 25, 50 and 100 mg PE/kg, respectively, once daily for 7 days. PE significantly suppressed the parasitaemia and showed significant efficacy in ameliorating anaemic conditions in P. chabaudi-infected mice in a dose-dependent manner. Histological investigation of the spleen tissue of treated and untreated mice further supports the antimalarial potential of PE. In addition, our study proved that Saudi PE reduced oxidative damage by decreasing the malondialdehyde (MDA) and increasing the catalase (CAT) activity and the glutathione (GSH) levels. Also, Saudi PE increased the level of some pro-inflammatory cytokines such as IFN-γ, TNF-α, GM-CSF and G-CSF, with the most effective dose being 100 mg PE/kg. In conclusion, PE showed antimalarial and antioxidant activities and provided protection against spleen tissue damage in P. chabaudi-infected mice.


Asunto(s)
Antimaláricos/administración & dosificación , Malaria/tratamiento farmacológico , Extractos Vegetales/administración & dosificación , Plasmodium chabaudi/efectos de los fármacos , Própolis/administración & dosificación , Sustancias Protectoras/administración & dosificación , Bazo/efectos de los fármacos , Animales , Femenino , Glutatión/metabolismo , Factor Estimulante de Colonias de Granulocitos/genética , Factor Estimulante de Colonias de Granulocitos/metabolismo , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Factor Estimulante de Colonias de Granulocitos y Macrófagos/metabolismo , Humanos , Malaria/genética , Malaria/metabolismo , Malaria/parasitología , Malondialdehído/metabolismo , Ratones , Parasitemia/tratamiento farmacológico , Parasitemia/genética , Parasitemia/metabolismo , Parasitemia/parasitología , Plasmodium chabaudi/fisiología , Arabia Saudita , Bazo/metabolismo , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo
2.
BMC Infect Dis ; 15: 170, 2015 Apr 02.
Artículo en Inglés | MEDLINE | ID: mdl-25886020

RESUMEN

BACKGROUND: The objective of this study was to explore effects of khat (Catha edulis) on outcome of rodent malaria infection and its anti-plasmodial activities on Plasmodium berghei ANKA (PbA). METHODS: Female Swiss albino mice were orally treated with crude khat (Catha edulis) extracts (100, 200 and 300 mg/kg) on a daily basis for 4 weeks prior to PbA infection. Physical, clinical, hematological, biochemical and histo-pathological features of the mice were assessed. In addition, in vivo anti-plasmodial activities of khat were evaluated. RESULTS: The finding of this study showed that khat use was strongly associated with increment of levels of liver and kidney biomarkers, leucopenia, severe anemia, rise in level of inflammation biomarkers: C-reactive protein (CRP), uric acid (UA), increased monocyte-lymphocyte count ratio (MLCR), manifestation of cerebral malaria symptoms such as ataxia, paralysis and deviation of the head but with no pulmonary edema. Significantly lower level of parasitemia (P<0.05), rectal temperature, but, high level of hemoglobin were observed at the early stage of the PbA infection in khat treated mice than the control. With extension of the treatment period, however, drastic increments were observed in parasite load and rectal temperature although there was reduction in hemoglobin (Hb) level. Moreover, khat showed poor anti-plasmodial activity with <10% parasite suppression activity and lack protection against major malaria symptoms. The significant reduction (P<0.01) of hematological parameters during PbA infection strengthen the notion that hematological parameters could be good predictors of severe malaria complications in human. CONCLUSIONS: In mice model treated with khat prior to infection with the rodent malaria parasite, khat was found to worsen manifestation of most malaria complications. Furthermore, the same plant showed poor in vivo anti-plasmodial activity and protection against major malaria symptoms.


Asunto(s)
Catha , Hemoglobinas/efectos de los fármacos , Malaria/metabolismo , Parasitemia/metabolismo , Extractos Vegetales/farmacología , Plasmodium berghei , Animales , Temperatura Corporal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/patología , Proteína C-Reactiva/efectos de los fármacos , Proteína C-Reactiva/inmunología , Modelos Animales de Enfermedad , Femenino , Hemoglobinas/metabolismo , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Recuento de Linfocitos , Malaria/inmunología , Malaria/fisiopatología , Ratones , Parasitemia/inmunología , Parasitemia/fisiopatología , Edema Pulmonar/inmunología , Edema Pulmonar/metabolismo , Edema Pulmonar/fisiopatología , Distribución Aleatoria , Ácido Úrico/inmunología
3.
Am J Clin Nutr ; 92(6): 1385-92, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20926522

RESUMEN

BACKGROUND: Iron deficiency anemia (IDA) affects many young women in sub-Saharan Africa. Its etiology is multifactorial, but the major cause is low dietary iron bioavailability exacerbated by parasitic infections such as malaria. OBJECTIVE: We investigated whether asymptomatic Plasmodium falciparum parasitemia in Beninese women would impair absorption of dietary iron or utilization of circulating iron. DESIGN: Iron absorption and utilization from an iron-fortified sorghum-based meal were estimated by using oral and intravenous isotope labels in 23 afebrile women with a positive malaria smear (asexual P. falciparum parasitemia; > 500 parasites/µL blood). The women were studied while infected, treated, and then restudied 10 d after treatment. Iron status, hepcidin, and inflammation indexes were measured before and after treatment. RESULTS: Treatment reduced low-grade inflammation, as reflected by decreases in serum ferritin, C-reactive protein, interleukin-6, interleukin-8, and interleukin-10 (P < 0.05); this was accompanied by a reduction in median serum hepcidin of ≈ 50%, from 2.7 to 1.4 nmol/L (P < 0.005). Treatment decreased serum erythropoietin and growth differentiation factor 15 (P < 0.05). Clearance of parasitemia increased geometric mean dietary iron absorption (from 10.2% to 17.6%; P = 0.008) but did not affect systemic iron utilization (85.0% compared with 83.1%; NS). CONCLUSIONS: Dietary iron absorption is reduced by ≈ 40% in asymptomatic P. falciparum parasitemia, likely because of low-grade inflammation and its modulation of circulating hepcidin. Because asymptomatic parasitemia has a protracted course and is very common in malarial areas, this effect may contribute to IDA and blunt the efficacy of iron supplementation and fortification programs. This trial was registered at clinicaltrials.gov as NCT01108939.


Asunto(s)
Anemia Ferropénica/metabolismo , Hierro de la Dieta/farmacocinética , Malaria Falciparum/metabolismo , Parasitemia/metabolismo , Plasmodium falciparum , Adolescente , Adulto , Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/etiología , Péptidos Catiónicos Antimicrobianos/sangre , Benin , Eritropoyetina/sangre , Femenino , Ferritinas/sangre , Alimentos Fortificados , Factor 15 de Diferenciación de Crecimiento/sangre , Hepcidinas , Humanos , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Inflamación/parasitología , Mediadores de Inflamación/sangre , Absorción Intestinal , Hierro de la Dieta/metabolismo , Marcaje Isotópico , Malaria Falciparum/complicaciones , Malaria Falciparum/tratamiento farmacológico , Parasitemia/tratamiento farmacológico , Sorghum , Adulto Joven
4.
Int J Parasitol ; 37(5): 525-37, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17157853

RESUMEN

Reduced plasma retinol concentrations occur in human malaria but the benefits of supplementation remain uncertain. We assessed the in vivo efficacy of retinol administration, and its effect on lipid peroxidation, in a Plasmodium berghei murine model. Animals received vehicle (n=17) or retinol (i) before P. berghei inoculation (four doses), (ii) at parasitaemia 10-15% (three to four doses) or (iii) before and after inoculation (six to seven doses; n=15 in each group), with euthanasia on day 8 post-inoculation or when the parasitaemia exceeded 50%. Multiple-dose pre-inoculation retinol reduced endpoint parasitaemia by 24% (P=0.001 versus controls). A reduction of 18% (P=0.042) was observed when retinol was given to parasitaemic animals. Retinol was ineffective when given both before and after infection (11% reduction; P=0.47). Although retinol supplementation did not change plasma retinol concentrations, liver retinol content increased and correlated inversely with endpoint parasitaemia (r=-0.45, P=0.001). Malaria infection augmented concentrations of the free radical lipid peroxidation end-product F(2)-isoprostanes in plasma, erythrocytes and liver by 1.8-, 2.8- and 4.9-fold, respectively, but retinol supplementation had no effect on these increases. Consistent with some human malaria studies, prophylactic retinol reduces P. berghei parasitaemia. This effect relates to augmentation of tissue retinol stores rather than to retinol-associated changes in oxidant status.


Asunto(s)
Antimaláricos/administración & dosificación , Peroxidación de Lípido/fisiología , Malaria/tratamiento farmacológico , Plasmodium berghei/aislamiento & purificación , Vitamina A/administración & dosificación , Administración Oral , Animales , Ácido Araquidónico/análisis , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Esquema de Medicación , F2-Isoprostanos/análisis , Ácidos Grasos Insaturados/análisis , Inyecciones Intraperitoneales , Hígado/metabolismo , Malaria/sangre , Malaria/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Parasitemia/dietoterapia , Parasitemia/metabolismo , Proyectos Piloto , Vitamina A/análisis , Vitamina A/sangre
5.
Proc Biol Sci ; 271(1546): 1385-91, 2004 Jul 07.
Artículo en Inglés | MEDLINE | ID: mdl-15306337

RESUMEN

Adaptive bias in sex allocation is traditionally proposed to be related to the condition of mothers as well as to the unequal fitness values of produced sexes. A positive relationship between mother condition and investment into male offspring is often predicted. This relationship was also recently found to depend on environmental conditions. We studied these causalities experimentally using a design where winter food supply was manipulated in eight outdoor-enclosed populations of field voles Microtus agrestis. At the beginning of the breeding season in spring, food-supplemented mothers seemed to be in a similar condition, measured as body mass, head width, body condition index and parasite load (blood parasite Trypanosoma), to non-supplemented mothers. Food supplements affected neither the litter size, the reproductive effort of mothers, nor the litter sex ratios at birth. However, food supplementation significantly increased the birth size of male offspring and improved their condition, as indicated by reduced parasite loads (intestinal Eimeria). Interestingly, mothers in good body condition produced larger male offspring only when environmental conditions were improved by food supplements. Although the adaptiveness of variation in mammalian sex ratios is still questionable, our study indicates that mothers in good condition bias their investment towards male offspring, but only when environmental conditions are favourable.


Asunto(s)
Arvicolinae/metabolismo , Suplementos Dietéticos , Ambiente , Intercambio Materno-Fetal/fisiología , Análisis de Varianza , Animales , Arvicolinae/parasitología , Arvicolinae/fisiología , Constitución Corporal , Pesos y Medidas Corporales , Eimeria , Femenino , Finlandia , Modelos Lineales , Tamaño de la Camada , Parasitemia/metabolismo , Embarazo , Reproducción/fisiología , Estaciones del Año , Factores Sexuales , Razón de Masculinidad , Trypanosoma
6.
FASEB J ; 18(3): 499-510, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15003995

RESUMEN

Malaria infection can cause cerebral symptoms without parasite invasion of brain tissue. We examined the relationships between brain biochemistry, bioenergetics, and gene expression in murine models of cerebral (Plasmodium berghei ANKA) and noncerebral (P. berghei K173) malaria using multinuclear NMR spectroscopy, neuropharmacological approaches, and real-time RT-PCR. In cerebral malaria caused by P. berghei ANKA infection, we found biochemical changes consistent with increased glutamatergic activity and decreased flux through the Krebs cycle, followed by increased production of the hypoxia markers lactate and alanine. This was accompanied by compromised brain bioenergetics. There were few significant changes in expression of mRNA for metabolic enzymes or transporters or in the rate of transport of glutamate or glucose. However, in keeping with a role for endogenous cytokines in malaria cerebral pathology, there was significant up-regulation of mRNAs for TNF-alpha, interferon-gamma, and lymphotoxin. These changes are consistent with a state of cytopathic hypoxia. By contrast, in P. berghei K173 infection the brain showed increased metabolic rate, with no deleterious effect on bioenergetics. This was accompanied by mild up-regulation of expression of metabolic enzymes. These changes are consistent with benign hypermetabolism whose cause remains a subject of speculation.


Asunto(s)
Encéfalo/metabolismo , Regulación de la Expresión Génica , Malaria/metabolismo , Proteínas del Tejido Nervioso/biosíntesis , Animales , Ácido Aspártico/metabolismo , Transporte Biológico , ADN Complementario/genética , Desoxiglucosa/metabolismo , Metabolismo Energético , Femenino , Perfilación de la Expresión Génica , Malaria/genética , Malaria Cerebral/genética , Malaria Cerebral/metabolismo , Ratones , Ratones Endogámicos CBA , Modelos Animales , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/fisiología , Resonancia Magnética Nuclear Biomolecular , Parasitemia/genética , Parasitemia/metabolismo , Plasmodium berghei
7.
Exp Parasitol ; 80(2): 186-93, 1995 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-7895830

RESUMEN

The in vitro growth of Plasmodium falciparum was reduced by 35 and 43% through high concentrations (5 mmole/liter) of magnesium in RPMI medium and magnesium-free medium, respectively, after 48 hr, whereas no significant inhibition could be observed under these conditions after 24 hr cultivation in the respective medium. Levels of magnesium between 0.5 and 3 mmole/liter showed no inhibitory effect on the in vitro growth of P. falciparum even after long-term exposure for 7 days. The 50 and 90% chloroquine inhibitory concentrations of the chloroquine-resistant strain K1 after 24 hr were reduced to some extent in the presence of magnesium at 5 mmole/liter, but less than in the presence of verapamil at 10 mumole/liter, which showed intrinsic activities at this concentration and which completely reversed resistance. However, high physiologic magnesium plasma levels were associated with a significantly longer survival time of NMRI mice infected with P. berghei strain ANKA, compared to normal physiological plasma magnesium levels. It is concluded that in the case of clinically symptomatic magnesium deficiency, supplementation of magnesium will not aggravate concomitant plasmodial infections and therefore should not be withheld.


Asunto(s)
Magnesio/farmacología , Malaria/parasitología , Parasitemia/parasitología , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Análisis de Varianza , Animales , Calcio/antagonistas & inhibidores , Cloroquina/farmacología , Medios de Cultivo , Relación Dosis-Respuesta a Droga , Resistencia a Medicamentos , Eritrocitos/efectos de los fármacos , Eritrocitos/parasitología , Femenino , Magnesio/efectos adversos , Magnesio/sangre , Malaria/metabolismo , Ratones , Parasitemia/metabolismo , Plasmodium berghei/crecimiento & desarrollo , Plasmodium falciparum/crecimiento & desarrollo , Factores de Tiempo , Verapamilo/farmacología
8.
Parasite ; 1(3): 219-26, 1994 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9140488

RESUMEN

The schizogony of malarial parasite is a typical cyclic phenomenon where the different stages of parasite development appear at regular time intervals. Each of the stages is specifically sensitive to different antimalarial drugs. Knowledge of the details of the cycle, drug susceptibility and the pharmacokinetics of drugs, could allow the improvement of drug action by the chronotherapeutic approach: treatment at the time of appearance of the drug sensitive stage with a drug that displays rapid pharmacokinetics. Since murine malarias serve as preferable models for in vivo drug testing, the pharmacokinetics of subcutaneously (sc) administered chloroquine (CQ) were tested in the whole blood of healthy mice and in animals slightly (1.5-3.5% parasitemia) or heavily infected (21-25% parasitemia) with Plasmodium chabaudi chabaudi. The half-time of absorption was around 5 min and almost independent of parasitemia. The apparent half-time of drug concentration decay was around 40 min in healthy animals, about 90 min at low parasitemia and about 410 min in heavy infection, indicating that the concentration of CQ is a typical spike, that is prolonged by asymptomatic disease, and considerably more by the active accumulation of CQ in infected cells. The latter is confirmed by the 3-fold higher peak blood [CQ] at the trophozoite stage and < 1.5-fold increase during schizogony. In conjunction with our previous experiments which showed that a single sc injection of 5 mg/kg CQ is sufficient to eliminate the drug susceptible mid-term trophozoite stage, the present results seem to justify to propose the chronotherapeutic approach for the treatment of malaria.


Asunto(s)
Antimaláricos/farmacocinética , Cloroquina/farmacocinética , Malaria/metabolismo , Parasitemia/metabolismo , Plasmodium chabaudi , Animales , Antimaláricos/administración & dosificación , Cloroquina/administración & dosificación , Ritmo Circadiano , Modelos Animales de Enfermedad , Inyecciones Intraperitoneales , Modelos Lineales , Masculino , Ratones , Análisis de Regresión
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA